About us

ABOUT US

CEVEC is a center of expertise for the production of biopharmaceuticals using a unique human cell-based expression system.

CAP-Go enables the production of proteins previously out of reach representing a significant proportion of the human proteome that is notoriously difficult to express in conventional cell lines such as CHO. The CAP-Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for the highly efficient production of a broad range of difficult to express recombinant proteins with authentic human post-translational modifications or on demand tailor made glycosylation patterns.

CAP-GT is a fully scalable manufacturing platform for viral vector production. CEVEC has successfully developed CAP-GT suspension cell-derived viral packaging cell lines, including a stable, helper virus-free AAV production platform, which enable better scale-up and competitive production costs when compared to adherent cell culture systems. CAP-GT suspension cell lines grow to high cell densities and show excellent productivity for a broad range of viruses. Gene therapy vectors such as lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV) can be produced at industrial scale.

Follow CEVEC on LinkedIn.

Management

Dr. Nicole Faust has extensive management experience in the biotechnology sector. Over the last 18 years she has held scientific management positions with Artemis/Taconic Biosciences, amaxa, Lonza, and CEVEC, engaging in the fields of pharmaceutical models, gene transfer, protein production, and gene therapy. She received her Ph.D. from University of Freiburg and an MBA degree from Educatis University, Switzerland.

DR. NICOLE FAUST

CEO & CSO

Dr. Nico Scheer adds more than 15 years of experience in business development, portfolio and project management, plus licensing and partnering activities in the life science industry as well as a strong scientific background in drug metabolism, molecular biology, and in vitro technologies. He holds a PhD in Molecular Developmental Biology and a PMI certified Project Management Professional (PMP).

DR. NICO SCHEER

Chief Business Officer

Dr. Nadine Sandhöfer joined CEVEC in 2015. She holds a PhD in human biology with a strong scientific background in tumor biology and in the field of targeted therapies. As a scientist and research manager, Nadine held positions with the Helmholtz Center Munich and the DKFZ Heidelberg. During her position in an ISO certified medical laboratory at the University Hospital Munich, she was trained and certified as quality management representative and internal auditor.

DR. NADINE SANDHÖFER

Director QA and Regulatory Affairs

Board

BART BERGSTEIN

Cofounder of Forbion Capital Partners
Former Life Science Venture Capitalist

CHRISTIAN LEIKERT

Investment Manager
at Creathor Venture

DR. ARISTOTELIS NASTOS

Head of Life Sciences
at NRW Bank Venture Fund

DR. JOACHIM RAUTTER

Partner at PEPPERMINTVENTURE PARTNERS
Chairman of the Board

DR. KLAUS ZIMMERMANN

Barrister-at-law

Scientific Advisory Board CAP®Go

PROF. DR. JÜRGEN HUBBUCH

Professor at Karlsruhe Institute of Technology
Head of the Institute of Engineering in Life
Section IV: Biomolecular Separation Engineering

PROF. DR. THOMAS NOLL

Professor and Chair for Cell Culture Technology
University of Bielefeld

Franz Nothelfer

Former Associate Director Protein Science
Boehringer Ingelheim Pharma GmbH & Co.KG

Scientific Advisory Board CAP®GT

PROF. DR. STEFAN KOCHANEK

Professor at the University of Ulm
and Director of the Department of Gene Therapy

DR. OTTO MERTEN

Head of Applied Vector Studies
Généthon

Dr. J. Fraser Wright

Chief Technology Officer
Axovant Sciences, Inc.

Investors

GAT Holding (Switzerland), CEVEC’s Chief Executive Officer and Chief Scientific Officer as well as other private investors are complementing the investor base of CEVEC Pharmaceuticals GmbH